Supriya Lifescience Ltd

The company was incorporated as Supriya Lifescience Limited on 26 March 2008 upon the conversion of M/s Supriya Chemicals,a partnership firm, into a public limited company.The company commenced operations on 01 April 2008.The company is engaged in manufacturing and export of active pharmaceutical ingredients(APIs).The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. As of 31 March 2021,the company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, antiasthmatic and antiallergic.The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 4555% and 6570%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The companys products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, antiasthmatic and antiallergic.The companys business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022. The new clean rooms will add manufacturing capacity of 215 KL per day.On 31 March 2012,the company has issued and allotted 3002400 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 12:1.On 31 March 2013,the company has issued and allotted 1626302 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 1:2.On 01 October 2015,the company has issued and allotted 9757804 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 2:1On 26 December 2020,the company has subdivided its face value of equity shares from Rs 10 each to Rs 2 each.During the month of December 2021,the company came out with an Rs 700crore public issue which comprised of a fresh issue of Rs 200 crore and an offer for sale(OFS) of Rs 500 crore by the promoter Satish Waman Wagh.The IPO shares were allotted at the price of Rs 274 per share including a premium of Rs 272 per share.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India Ltd(NSE) on 28 December 2021.